KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

West Pharmaceutical Services (WST) EBIAT (2016 - 2025)

West Pharmaceutical Services' EBIAT history spans 17 years, with the latest figure at $128.2 million for Q4 2025.

  • For Q4 2025, EBIAT changed 0.08% year-over-year to $128.2 million; the TTM value through Dec 2025 reached $487.7 million, down 0.61%, while the annual FY2025 figure was $479.3 million, 0.27% changed from the prior year.
  • EBIAT for Q4 2025 was $128.2 million at West Pharmaceutical Services, down from $137.9 million in the prior quarter.
  • Across five years, EBIAT topped out at $188.5 million in Q2 2022 and bottomed at $89.8 million in Q1 2025.
  • The 5-year median for EBIAT is $137.4 million (2023), against an average of $141.0 million.
  • The largest annual shift saw EBIAT surged 113.37% in 2021 before it crashed 31.32% in 2022.
  • A 5-year view of EBIAT shows it stood at $147.7 million in 2021, then plummeted by 30.26% to $103.0 million in 2022, then surged by 33.01% to $137.0 million in 2023, then dropped by 6.5% to $128.1 million in 2024, then increased by 0.08% to $128.2 million in 2025.
  • Per Business Quant, the three most recent readings for WST's EBIAT are $128.2 million (Q4 2025), $137.9 million (Q3 2025), and $131.8 million (Q2 2025).